TITLE

A comparison of ARMS and mutation specific IHC for common activating EGFR mutations analysis in small biopsy and cytology specimens of advanced non small cell lung cancer

AUTHOR(S)
Xueqing Wang; Guoqing Wang; Yueyue Hao; Yinhong Xu; Lihua Zhang
PUB. DATE
July 2014
SOURCE
International Journal of Clinical & Experimental Pathology;2014, Vol. 7 Issue 7, p4310
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
No abstract available.
ACCESSION #
97436132

 

Related Articles

  • Intratumoral distribution of EGFR mutations and copy number in metastatic lung cancer, what impact on the initial molecular diagnosis? Mansuet-Lupo, Audrey; Zouiti, Fouzia; Alifano, Marco; Tallet, Anne; Charpentier, Marie-Christine; Ducruit, Véronique; Devez, Fabrice; Lemaitre, Fanny; Laurent-Puig, Pierre; Damotte, Diane; Blons, Hélène // Journal of Translational Medicine;2014, Vol. 12 Issue 1, p1 

    Background Activating epidermal growth factor receptor (EGFR) mutations characterize a subgroup of non-small-cell lung cancer that benefit from first line EGFR tyrosine kinase inhibitors (EGFR-TKI). However, the existence of polyclonal cell populations may hinder personalized-medicine strategies...

  • EGFR mutation testing in lung cancer: a review of available methods and their use for analysis of tumour tissue and cytology samples. Ellison, Gillian; Guanshan Zhu; Moulis, Alexandros; Dearden, Simon; Speake, Georgina; McCormack, Rose // Journal of Clinical Pathology;Feb2013, Vol. 66 Issue 2, p79 

    Aims Activating mutations in the gene encoding epidermal growth factor receptor (EGFR) can confer sensitivity to EGFR tyrosine kinase inhibitors such as gefitinib in patients with advanced non-small-cell lung cancer. Testing for mutations in EGFR is therefore an important step in the...

  • The use of mutation-specific antibodies in predicting the effect of EGFR-TKIs in patients with non-small-cell lung cancer. Zhao, Jingya; Wang, Xiaoying; Xue, Liang; Xu, Nuo; Ye, Xin; Zeng, Haiying; Lu, Shaohua; Huang, Jie; Akesu, Sujie; Xu, Chen; He, Deming; Tan, Yunshan; Hong, Qunying; Wang, Qun; Zhu, Guanshan; Hou, Yingyong; Zhang, Xin // Journal of Cancer Research & Clinical Oncology;May2014, Vol. 140 Issue 5, p849 

    Purpose: We aimed to quantify the epidermal growth factor receptor (EGFR) mutation in tumors and to analyze its prediction of EGFR-tyrosine kinase inhibitor (EGFR-TKI) treatment efficacy in EGFR mutation-positive non-small-cell lung cancer (NSCLC) patients. Methods: We examined EGFR mutation...

  • Suitability of Small Bronchoscopic Tumour Specimens for Lung Cancer Genotyping. Dooms, Christophe; Vliegen, Liesbet; Vander Borght, Sara; Yserbyt, Jonas; Hantson, Inge; Verbeken, Eric; Wauters, Els; Nackaerts, Kristiaan; Ninane, Vincent; Vansteenkiste, Johan; Vandenberghe, Peter // Respiration;Nov2014, Vol. 88 Issue 5, p371 

    Background: Biomarker-driven clinical trials in advanced non-small cell lung cancer (NSCLC) usually accept biopsy specimens only, as cytology specimens are supposed to be more challenging due to low neoplastic cell content and suboptimal DNA quantity. Objectives: We aimed to evaluate 2 aspects...

  • Immunohistochemical detections of EGFR status in NSCLC. Jie WANG; Chang LIU; Diansheng ZHONG; Dongbo XU; Chao NING; Qing MA // Chinese Journal of Lung Cancer;4/20/2015, Vol. 18 Issue 4, p212 

    Background and objective Patients with non-small cell lung cancer (NSCLC) harboring mutations of the epidermal growth factor receptor (EGFR) respond well to EGFR-tyrosine kinase inhibitor therapy. Immunohistochemistry (IHC) is a simple and widely used technique in clinical pathology...

  • Comprehensive epidermal growth factor receptor gene analysis from cytological specimens of non-small-cell lung cancers. Savic, S.; Tapia, C.; Grilli, B.; Rufle, A.; Bihl, M. P.; de Vito Barascud, A.; Herzog, M.; Terracciano, L.; Baty, F.; Bubendorf, L. // British Journal of Cancer;1/1/2008, Vol. 98 Issue 1, p154 

    Epidermal growth factor receptor (EGFR) gene mutations and increased copy numbers are considered as predictors of response to EGFR tyrosine kinase inhibitors (EGFR-TKI) in non-small-cell lung cancer (NSCLC). Lung cancer diagnosis is often based on cytology alone. However, almost all published...

  • Next-Generation Sequencing of Lung Cancer EGFR Exons 18-21 Allows Effective Molecular Diagnosis of Small Routine Samples (Cytology and Biopsy). de Biase, Dario; Visani, Michela; Malapelle, Umberto; Simonato, Francesca; Cesari, Valentina; Bellevicine, Claudio; Pession, Annalisa; Troncone, Giancarlo; Fassina, Ambrogio; Tallini, Giovanni // PLoS ONE;Dec2013, Vol. 8 Issue 12, p1 

    Selection of lung cancer patients for therapy with tyrosine kinase inhibitors directed at EGFR requires the identification of specific EGFR mutations. In most patients with advanced, inoperable lung carcinoma limited tumor samples often represent the only material available for both histologic...

  • Assessment of Epidermal Growth Factor Receptor and K-Ras Mutation Status in Cytological Stained Smears of Non-Small Cell Lung Cancer Patients: Correlation with Clinical Outcomes. Lozano, Maria D.; Zulueta, Javier J.; Echeveste, Jose I.; Gérpide, Alfonso; Seijo, Luis M.; Martön-Algarra, Salvador; Del Barrio, Anabel; Pio, Ruben; Idoate, Miguel Angel; Labiano, Tania; Perez-Gracia, Jose Luis // Oncologist;Jun2011, Vol. 16 Issue 6, p877 

    Objective. Epidermal growth factor receptor (EGFR) and K-ras mutations guide treatment selection in non-small cell lung cancer (NSCLC) patients. Although mutation status is routinely assessed in biopsies, cytological specimens are frequently the only samples available. We determined EGFR and...

  • Molecular Diagnosis in Cytology and Its Place in the New Classification: A Practical Guide. O'Toole, Sandra A.; Bing Yu; Cooper, Wendy // Journal of OncoPathology;Mar2014, Vol. 2 Issue 1, p63 

    The clinical importance of molecular testing for Epidermal Growth Factor Receptor (EGFR) mutations and ALK gene rearrangements in non-small cell lung cancer (NSCLC) is widely recognized. As most patients with NSCLC present with advanced stage disease not suitable for surgical resection, only...

  • Ascertaining an Appropriate Diagnostic Algorithm Using EGFR Mutation-Specific Antibodies to Detect EGFR Status in Non-Small-Cell Lung Cancer. Jiang, Guiyang; Fan, Chuifeng; Zhang, Xiupeng; Dong, Qianze; Wang, Liang; Liu, Yang; Dai, Shundong; Yang, Lianhe; Zhang, Yong; Yu, Juanhan; Wang, Enhua // PLoS ONE;Mar2013, Vol. 8 Issue 3, p1 

    Background: Epidermal growth factor receptor (EGFR) mutation status is the most valuable indicator in the screening of non-small-cell lung cancer (NSCLC) patients for tyrosine kinase inhibitor (TKI) therapy. Accurate, rapid and economical methods of detecting EGFR mutations have become...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics